This is a routine deal-progression amendment with no material change to the merger's economics. Monitor for the filing of the Form S-4 proxy statement and the stockholder vote date, which will be the next key catalysts. The lowered voting threshold (majority of votes cast vs. outstanding) increases the probability of approval.
Price Chart
Executive Summary
Boundless Bio (BOLD) and Serapha Bio entered into Amendment No. 1 to their Merger Agreement, making technical clarifications to definitions, adding mechanics for converting Serapha RSUs into Boundless Bio restricted stock units, and allowing pre-funded warrants to be issued as merger consideration to avoid exceeding beneficial ownership limits. The amendment also lowers the voting standard for increasing authorized shares from a majority of outstanding shares to a majority of shares cast. This is a routine deal-progression filing that does not change the fundamental economics or timeline of the previously announced merger.
Key Financial Metrics
Key Facts
- Amendment No. 1 to the Merger Agreement was entered into on August 28, 2026.
- Serapha RSUs (vested or unvested) will convert into Assumed RSUs covering Boundless Bio common stock, adjusted by the Exchange Ratio.
- Pre-funded warrants with an exercise price of $0.00001 per share may be issued as Merger Consideration in lieu of Boundless Bio common stock to respect beneficial ownership limitations.
- The voting standard for increasing authorized shares of Boundless Bio common stock was changed to a majority of shares properly cast, rather than a majority of outstanding shares.
- The Company Pre-Closing Financing must deliver aggregate gross cash proceeds of not less than the 'Company Pre-Closing Financing Minimum Amount' (amount not disclosed).
Financial Impact
No financial figures disclosed; the amendment is procedural and does not alter the deal value or exchange ratio.
Risk Factors
- Risk that the Company Pre-Closing Financing minimum amount is not met, which is a condition to closing.
- Risk that required stockholder approval is not obtained despite the lowered voting threshold.
- Risk that the merger does not close on the expected timeline or at all.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (BOLD) — Batch item 1 | 0001193125-26-374789 |
| Document: 0001193125-26-374789-index-headers.html | 0001193125-26-374787 |
| Document: 0001193125-26-374789-index.html | 0001193125-26-374789 |
| Document: 0001193125-26-374789.txt | 0001193125-26-374789 |
| 8-K Filing (BOLD) — Batch item 5 | 0001193125-26-374787 |
| Document: 0001193125-26-374787-index.html | 0001193125-26-374789 |
| Document: 0001193125-26-374787.txt | 0001193125-26-374789 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 425 | $2.41 | awaiting T+20 | — | $2.41 (+0.00%) |
Oct 26, 2026 today | 425 | $2.45 | awaiting T+20 | — | $2.41 (−1.63%) |
Oct 8, 2026 18d ago | S-4 | $2.53 | awaiting T+20 | — | $2.41 (+4.74%) |
Aug 28, 2026 8w ago | 425 / 8-K | $2.81 $2.56 | ▼ −8.90% | ▼ −8.53% | $2.41 (−14.23%) |
Jul 8, 2026 15w ago | Insider Cluster | $2.51 $2.84 | ▲ +13.15% | ▲ +10.91% | $2.41 (−3.98%) |
Jul 6, 2026 16w ago | Insider Cluster | $2.50 $2.71 | ▲ +8.20% | ▲ +5.04% | $2.41 (−3.60%) |
Jun 29, 2026 17w ago | 3 | $2.50 $2.48 | ▼ −0.80% | ▲ +0.23% | $2.41 (−3.60%) |
May 8, 2026 24w ago | 8-K | $1.44 $1.42 | ▼ −1.39% | ▼ −1.41% | $2.41 (+67.36%) |
May 8, 2026 24w ago | Press Release | $1.44 $1.42 | ▲ +1.39% | ▲ +1.41% | $2.41 (−67.36%) |
Apr 17, 2026 27w ago | Press Release | $1.60 $1.42 | ▼ −11.25% | ▼ −15.45% | $2.41 (+50.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers